Citius Oncology, Inc.
corporate_fare Company Profile
Citius Oncology, Inc. (NASDAQ:CTOR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for CTOR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for CTOR spans 8-K, 424B3, 10-Q, SCHEDULE 13D/A.
Recent high-impact activity:
- Citius Oncology: LYMPHIR Wholesaler Units Jump 120% in Fiscal Q4
- Citius Oncology Wins Nasdaq Extension to April 19, 2027 to Reclaim $1.00 Bid
- Citius Oncology Files Prospectus Supplement: Board Expansion, Q3 Losses, Going Concern Warning
- Citius Oncology's Q3 Loss, Going Concern Warning, and Nasdaq Delisting Risk
- Citius Oncology Q3 FY2026: $7.1M Revenue, 44 Institutions Ordering LYMPHIR
Financial Snapshot
Short Interest & Short Volume
1.19 days to coverFINRA reported short interest of 201,913 shares in CTOR as of the October 30, 2026 settlement, a 11.2% decrease from the prior period — about 1.2 days to cover at its recent average daily volume. On November 20, 2026, 22.5% of CTOR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CTOR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-01.
Resale Registration Filed · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →